Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on April 27, 2017, regarding an event that occurred on April 25, 2017. The company is incorporated in Delaware and is headquartered in Ness Ziona, Israel. It is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Dr. Jerome B. Zeldis from the Board of Directors, effective immediately on April 25, 2017. The resignation was attributed to time commitments required for his service on other public company boards and was explicitly stated to be unrelated to any disagreement with the Company. Dr. Zeldis will continue to serve as a member of the Company's scientific advisory board.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's departure.
Investor Verification Checklist
- Verify the correct registrant name is AIT Therapeutics, Inc., not Beyond Air, Inc.
- Confirm the immediate resignation of Dr. Jerome B. Zeldis from the Board of Directors.
- Note that Dr. Zeldis remains on the scientific advisory board.
- Check subsequent filings for the appointment of a replacement director.